J Med Microbiol Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goff, D. A.
Right arrow Articles by Dowzicky, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goff, D. A.
Right arrow Articles by Dowzicky, M. J.
Agricola
Right arrow Articles by Goff, D. A.
Right arrow Articles by Dowzicky, M. J.
J Med Microbiol 56 (2007), 1189-1193; DOI: 10.1099/jmm.0.46710-0
© 2007 Society for General Microbiology
ISSN 1473-5644

Prevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial

Debra A. Goff1 and Michael J. Dowzicky2

1 The Ohio State University Medical Center, Department of Pharmacy, Columbus, OH 43210, USA

2 Wyeth Pharmaceuticals, Collegeville, PA, USA

Correspondence
Debra A. Goff
debbie.goff{at}osumc.edu

Received 10 May 2006
Accepted 13 February 2007

The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) is a surveillance study established in 2004 to monitor the activity of tigecycline, the first glycylcycline, and comparator agents [ß-lactams (including penicillins, cephalosporins and carbapenems), glycopeptides, tetracyclines, fluoroquinolones and oxazolidinones] against Gram-positive and Gram-negative pathogens worldwide. This report examines 1692 isolates of Staphylococcus aureus collected in the continental United States between January 2004 and September 2005. Meticillin-resistant S. aureus (MRSA) accounted for 52.0 % of isolates. Prevalence of MRSA by state ranged from 12.5 % in New Hampshire to 100 % in Kentucky. All isolates were susceptible to tigecycline, linezolid and vancomycin. In vitro, tigecycline was potent against both meticillin-susceptible S. aureus (MSSA) (MIC50 and MIC90=0.12 µg ml–1) and MRSA (MIC50=0.12 µg ml–1; MIC90=0.25 µg ml–1). Only a single isolate was resistant to three or more antimicrobial classes. Ninety-six isolates (5.7 %) were susceptible to the complete antimicrobial panel.

Abbreviations: cIAI; complicated intra-abdominal infection; MRSA, meticillin-resistant Staphylococcus aureus; CA-MRSA, community-associated MRSA; HA-MRSA, healthcare-acquired MRSA; MSSA, meticillin-susceptible S. aureus; SSSI, skin and skin-structure infection.

All MIC testing was done locally following a standard protocol.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 2007 Society for General Microbiology.